This is a preview of subscription content, log in to check access.
Kuechle MK, Stegemeir E, Maynard B, et al. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol 1994; 30: 187–92.CrossRefPubMedGoogle Scholar
Bouldin MB, Clowers-Webb HE, Davis JL, et al. Naproxenassociated linear IgA bullous dermatosis: case report and review. Mayo Clin Proc 2000; 75: 967–70.CrossRefPubMedGoogle Scholar
Wojnarowska F, Marsden RA, Bhogal B, et al. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol 1988; 19: 792–805.CrossRefPubMedGoogle Scholar
Chanal J, Ingen-Housz-Oro S, Ortonne N, et al. Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol 2013; 169: 1041–8.CrossRefPubMedGoogle Scholar
Plunkett RW, Chiarello SE, Beutner EH. Linear IgA bullous dermatosis in one of two piroxicam-induced eruptions: a distinct direct immunofluorescence trend revealed by the literature. J Am Acad Dermatol 2001; 45: 691–6.CrossRefPubMedGoogle Scholar
Lings K, Bygum A. Linear IgA bullous dermatosis: a retrospective study of 23 patients in Denmark. Acta Derm Venereol 2015; 95: 466–71.CrossRefPubMedGoogle Scholar
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45.CrossRefPubMedGoogle Scholar